Expiration Date: April 29, 2017
Media: Internet - based
This activity is designed to update physicians on the most clinically impactful data presented at the 2016 Genitourinary Cancers Symposium so that they can assess and prepare to apply these findings to their clinical practice to improve patient care.
CME Activity Table of Contents
- IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC)
- CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC)
- Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC)
- NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA
- Hypofractionated radiotherapy (RT) schedules in patients with low-risk prostate cancer: the RTOG 0415 and CHHiP trials
- (NGS) Actionable targets in patients with cisplatin-resistant advanced germ cell tumors (GCT)
Instructions For This Activity & Receiving Credit
This educational program is directed toward all attendees of the 2016 Genitourinary Cancers Symposium including medical, surgical, and radiation oncologists and urologists involved in the treatment of patients with GU malignancies. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, nuclear medicine physicians, and other health care professionals, interested in the treatment of GU malignancies, may also participate.
At the conclusion of this activity, you should be better prepared to:
- Summarize recent treatment advances for advanced GU cancers, and their impact on clinical decision making and patient outcomes.
- Evaluate data on emerging treatments and their potential impact on the future treatment landscape for GU cancers.
- Evaluate the benefit of clinical trial participation for improving outcomes among patients with GU cancers and limited treatment options.
Faculty, Staff, and Planners' Disclosures
Daniel P Petrylak, MD
Professor of Medicine, Medical Oncology
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Program
Yale Cancer Center
New Haven, CT
Disclosure: Grant/Research Support: Bayer, Bellicum Pharmaceuticals, Dendreon, Sanofi-Aventis, Johnson & Johnson, Exelixis, Ferring Pharmaceuticals, Millennium Pharmaceuticals, Medivation, Pfizer, Roche Laboratories, Tyme, Inc. Consultant: Bayer, Bellicum Pharmaceuticals, Dendreon, Sanofi-Aventis, Johnson & Johnson, Exelixis, Ferring Pharmaceuticals, Millennium Pharmaceuticals, Medivation, Pfizer, Roche Laboratories, Tyme, Inc.
Primo N Lara, Jr, MD
Professor of Medicine
Associate Director for Translational Research
UC Davis Comprehensive Cancer Center
Disclosure: Honoraria: Pfizer. Consulting/Advisory Role: Clovis Oncology, Pfizer, Teva Pharmaceutical, Halozyme Therapeutics, Novartis, Sanofi, Lpath, Lilly, AstraZeneca, Bayer, Genentech/Roche. Research Funding: Millennium, Polaris, OncoGenex Pharmaceuticals, GlaxoSmithKline, Genentech, Aragon Pharmaceuticals, Janssen Biotech, Heat Biologics.
The following individuals have no relevant financial relationships with commercial interests:
The staff of PER®, LLC.
Disclosure Policy and Resolution of Conflicts of Interest (COI)
It is the policy of Physicians' Education Resource®, LLC, (PER®) to ensure fair balance, independence, objectivity, and scientific rigor in all of our CME/CE activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as a part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
Off-Label Disclosure and Disclaimer
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
Hardware And Software Requirements
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)
Minimum System Requirements (Windows)
- A Pentium-based PC or compatible computer
- At least 64MB of RAM
- Windows 95/98/NT/ME/2000/XP/Vista system software
- Screen resolution of 1024 x 786 or larger recommended
- PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise